GST001 is Gesthera’s lead development program for spontaneous preterm labor. It is described as a novel, orally available small molecule that selectively targets the prostaglandin F2α receptor.
The development rationale is based on targeting inflammation and uterine contractions while aiming to reduce some of the fetal risks associated with non-specific prostaglandin inhibition. This selective mechanism of action is one of the key differentiating features of GST001.
Gesthera’s existing development package includes preclinical studies, Phase 1 work and a Phase 2a proof-of-concept program. The presentation reports no identified safety concerns in the earlier studies and describes dose-dependent inhibition of contractions induced by PGF2α or oxytocin.
These results form the foundation for the next stages of clinical development and for Gesthera’s broader strategy in women’s health.
